Weekly GLP-1 News Roundup (Oct 23, 2026): A Pill Nears Europe, CagriSema Data, and New Pregnancy Guidance
Happy Friday, flock! 🐦 Another week, another stack of GLP-1 headlines. This week brought a new pill one step closer to Europe, fresh data on a next-gen injection, a compounding recall, a look at how GLP-1 users are changing their shopping carts, and new pregnancy guidance from the nation’s ob-gyns. Grab your coffee (or your water bottle 💧) and let’s dive in. Want the deeper dive? Every story below has a full article right here on the blog. 📖
💊 Europe Says “Almost Yes” to Lilly’s Foundayo Pill
On Oct. 16, the European Medicines Agency’s drug committee recommended approving Eli Lilly’s once-daily oral GLP-1, Foundayo (orforglipron), for weight management and type 2 diabetes in adults. The European Commission still has to give the final sign-off. If it does, Foundayo would be the second weight-loss pill backed in the EU after Novo Nordisk’s Wegovy pill. Foundayo has been on sale in the U.S. since April and in the UK since August.
📈 CagriSema’s Numbers Look Bigger for Women
Novo Nordisk shared new after-the-fact analyses of its late-stage REDEFINE 1 trial of CagriSema, an experimental weekly shot that pairs semaglutide with cagrilintide. Women in the trial lost about 25% of their body weight on average at 68 weeks, assuming everyone stayed on treatment, and results held up across pre-, peri- and postmenopausal groups. Novo says these analyses only generate hypotheses and need more study. CNBC reports the drug is expected to launch early next year.
Sources: CNBC · Novo Nordisk · Reuters
⚠️ Compounded Tirzepatide Recall
Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of its compounded tirzepatide, a copycat of Lilly’s Zepbound, saying it couldn’t fully guarantee the product’s safety. The FDA classified it as a Class II recall. The recall comes as Lilly and Novo keep pushing, in court and elsewhere, to shut down the market for knockoff GLP-1s.
Sources: BioPharma Dive · FDA Enforcement Report
🛒 Weight Loss Is Now the Top Reason People Use GLP-1s
A survey of almost 15,000 people by consulting firm EY-Parthenon found that about 54% of U.S. GLP-1 users now take them mainly for weight loss, ahead of diabetes and other conditions. Users reported buying fewer sweet and salty snacks, and many have bought smaller or more fitted clothes. Retailers and food makers are adding protein-focused foods and smaller portion sizes in response.
🤰 New ACOG Guidance on GLP-1s, Pregnancy and Breastfeeding
On Oct. 23, the American College of Obstetricians and Gynecologists released a practice advisory to help ob-gyns counsel patients about GLP-1s before, during and after pregnancy. The group says there isn’t enough safety data yet. It advises against use during pregnancy and suggests clinicians discuss stopping a month or two before conception, since many of these drugs take a while to leave the body. For breastfeeding, ACOG recommends shared decision-making, with specific cautions for newborns and preterm infants.
Sources: ACOG · ACOG Practice Advisory
🩺 Before You Change Anything
Wondering how any of this news applies to you? Please check with your doctor or pharmacist before you make any changes to your treatment. They know your full health picture.
💬 Come Chat With the Flock!
Which headline caught your eye this week? Come share your thoughts in the GLP-1 News & Chat thread on our forum. We’d love to hear from you! 🐦💙